6312-72-7

Basic information

• Product Name: 5-BROMO-2,4-DIAMINO-6-HYDROXYPYRIMIDINE
• Synonyms: 5-BROMO-2,4-DIAMINO-6-HYDROXYPYRIMIDINE;2,6-diamino-5-bromo-1H-pyrimidin-4-one;2,6-Diamino-5-bromopyrimidin-4(1H)-one;2,6-Diamino-5-bromopyrimidine-4-ol;2,6-bis(azanyl)-5-bromo-1H-pyrimidin-4-one;2,4-DiaMino-6-hydroxy-5-broMopyriMidine;2,6-DiaMino-5-broMo-4(3H)-pyriMidinone;NSC 40393
• CAS NO: 6312-72-7
• Molecular Formula: C₄H₅BrN₄O
• Molecular Weight: 205.01
• EINECS: 228-637-1
• Product Categories: Pyridines, Pyrimidines, Purines and Pteredines;Nucleotides and Nucleosides;Bases & Related Reagents;Nucleotides
• Mol File: 6312-72-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 265°C
• Boiling Point: 273.4°C at 760 mmHg
• Flash Point: 119.1°C
• Appearance: /
• Density: 2.52g/cm³
• Vapor Pressure: 0.00575mmHg at 25°C
• Refractive Index: 1.867
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 8.84±0.50(Predicted)
• CAS DataBase Reference: 5-BROMO-2,4-DIAMINO-6-HYDROXYPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2,4-DIAMINO-6-HYDROXYPYRIMIDINE(6312-72-7)
• EPA Substance Registry System: 5-BROMO-2,4-DIAMINO-6-HYDROXYPYRIMIDINE(6312-72-7)

Safety Data

• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36:Wear suitable prot
• Hazardous Substances Data: 6312-72-7(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

InChI:InChI=1/C4H5BrN4O/c5-1-2(6)8-4(7)9-3(1)10/h(H5,6,7,8,9,10)

Upstream product

• 56-06-4 2,6-diaminopyrimidin-4-ol 
• 97925-57-0 thioxo-acetic acid 
• 100643-27-4 2,6-diamino-3H-pyrimidin-4-one 

Downstream Products

• 73573-51-0 (S)-6-methyl-5,6,7,8-tetrahydropterin 
• 79493-89-3 (S)-7-methyl-5,6,7,8-tetrahydropterin 
• 22288-75-1 2,4-diamino-6-hydroxy-5-thiocyanatopyrimidine 
• 173037-34-8 diethyl N-<4-(trans-2-<(<2,6-diamino-4-(3H)-oxopyrimidin-5-yl>thio)methyl>cyclobutyl)benzoyl>L-glutamate 
• 289677-60-7 4-[4-(2,4-diamino-6-oxo-1,6-dihydro-pyrimidin-5-ylsulfanylmethyl)-imidazol-1-ylmethyl]-benzoic acid methyl ester 
• 289677-65-2 4-[5-(2,4-diamino-6-oxo-1,6-dihydro-pyrimidin-5-ylsulfanylmethyl)-pyridin-3-yl]-benzoic acid methyl ester 
• 193064-84-5 2(S)-[(3-{3-[(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)sulfanyl]propyl}benzoyl)amino]pentanedioic acid diethyl ester 
• 157848-23-2 4-({3-[(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)sulfanyl]-3-[1,3]dioxolan-2-yl}propyl)benzoic acid methyl ester 
• 193065-03-1 3-{3-[(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)sulfanyl]-3-[1,3]dioxolan-2-ylpropyl}benzoic acid methyl ester 
• 160743-77-1 4-{3-[(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)sulfanyl]propyl}benzoic acid methyl ester 
• 160744-21-8 Methyl 4-(2-[(2,6-diamino-4(3H)-oxopyrimidin-5-yl)thio]ethyl)benzoate 
• 22288-77-3 2,5-diaminothiazolo<4,5-d>pyrimidin-7(6H)-one 
• 99845-50-8 2-(2,4-diamino-6-oxo-1,6-dihydro-pyrimidin-5-ylmercapto)-benzoic acid 

Relevant articles and documents

Mild regioselective monobromination of activated aromatics and heteroaromatics with N-bromosuccinimide in tetrabutylammonium bromide

Highly regioselective nuclear bromination of activated aromatic and heteroaromatic compounds has been accomplished using N-bromosuccinimide in tetrabutylammonium bromide. Pre-dominant para-selective monobromination of activated aromatics such as phenols and anilines, rate acceleration of bromination for moderately activated and less reactive substrates on addition of acidic montmorillonite K-10 clay, with or without microwave assistance, are the notable features of this protocol.

Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds

The present invention is directed to derivatives of 5-thia- and 5-selenopyrimidinone, which are useful as inhibitors of the enzymes glycinamide ribonucleotide formyl transferase (GARFT) and amino imidazole carboxamide ribonucleotide formyl transferase AICARFT), pharmaceutical compositions containing these derivatives, and methods of using these derivatives. The present invention is also directed to intermediates useful for preparing these derivatives and methods of preparing these intermediates.

Studies in the heterocyclic series. VIII. The first synthesis of a triazaphenothiazine ring

-